142 related articles for article (PubMed ID: 19038762)
1. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.
Ocio EM; Mateos MV; Maiso P; Pandiella A; San-Miguel JF
Lancet Oncol; 2008 Dec; 9(12):1157-65. PubMed ID: 19038762
[TBL] [Abstract][Full Text] [Related]
2. New drugs for treatment of multiple myeloma.
Bruno B; Rotta M; Giaccone L; Massaia M; Bertola A; Palumbo A; Boccadoro M
Lancet Oncol; 2004 Jul; 5(7):430-42. PubMed ID: 15231250
[TBL] [Abstract][Full Text] [Related]
3. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Catley L; Tai YT; Chauhan D; Anderson KC
Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
[TBL] [Abstract][Full Text] [Related]
4. New drugs in multiple myeloma.
Berenson JR; Yellin O
Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Kalmadi SR; Hussein MA
Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.
Allegra A; Sant'antonio E; Penna G; Alonci A; D'Angelo A; Russo S; Cannavò A; Gerace D; Musolino C
Eur J Haematol; 2011 Feb; 86(2):93-110. PubMed ID: 21114539
[TBL] [Abstract][Full Text] [Related]
7. Understanding novel therapeutic agents for multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
[TBL] [Abstract][Full Text] [Related]
8. New targets for lymphoma treatment.
Johnson PW
Ann Oncol; 2008 Jun; 19 Suppl 4():iv56-9. PubMed ID: 18519406
[No Abstract] [Full Text] [Related]
9. Overview of drug therapy for multiple myeloma.
Saunders G
J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
[TBL] [Abstract][Full Text] [Related]
10. Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Singla A; Kumar S
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():32-43. PubMed ID: 25188483
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibitors as therapy for multiple myeloma.
Usmani SZ; Chiosis G
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S77-81. PubMed ID: 22035754
[TBL] [Abstract][Full Text] [Related]
12. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction inhibitors in the treatment of breast cancer.
Nahta R; Hortobagyi GN; Esteva FJ
Curr Med Chem Anticancer Agents; 2003 May; 3(3):201-16. PubMed ID: 12769778
[TBL] [Abstract][Full Text] [Related]
17. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted therapies and combinations for the treatment of multiple myeloma.
Agarwal A; Mahadevan D
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
[TBL] [Abstract][Full Text] [Related]
20. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
